Skip to content

Recursion Pharmaceuticals, Inc.

RXRX· NasdaqCore metricsCIK 1601830

Biological products, except diagnostic substances175 peers

Last sale
Nov 12, 2026 · -7.39%
Market cap
$2.07B
622.76M shares
Filings
993
$18.55M
Q3 2026+26.9% FY25 yoy
-$119.04M
Q3 2026N/M FY25 yoy
-$123.18M
Q3 2026N/M FY25 yoy
-$265.16M
Q3 2026derivedN/M FY25 yoy
-$0.22
Q3 2026N/M FY25 yoy
$549.85M
Q3 2026+25.1% FY25 yoy
$2.07B
—
30.3×
2.3×
-15.11%
—

Twelve months to Sep 30, 2026 · derived

Price

$3.3229.51%$1.39past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$74.68MFY 2025
$74.68M0FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$74,681,000reported
FY 20242024-12-31$58,839,000reported
FY 20232023-12-31$44,575,000reported
FY 20222022-12-31$39,843,000reported
FY 20212021-12-31$10,178,000reported
FY 20202020-12-31$3,962,000reported
FY 20192019-12-31$2,319,000reported

Segments

Revenue by Geography, FY2023 to FY2025FY2023United States · FY2023 · $43.81MOther · FY2023 · $769.00KFY2024United States · FY2024 · $57.38MUnited Kingdom · FY2024 · $1.14MOther · FY2024 · $327.00KFY2025United States · FY2025 · $39.34MUnited Kingdom · FY2025 · $35.34M
LineFY2025ShareChange
United States$39.34M53%−31.4%
United Kingdom$35.34M47%+3,013.4%
Other$0.00—−100.0%
Total$74.68M

From the 10-K filed Feb 25, 2026RXRX

Biological products, except diagnostic substances

Recursion Pharmaceuticals, Inc. is the 35th largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Recursion Pharmaceuticals, Inc. · CIK 1601830 · Engraved from SEC EDGAR